NewsBenzingaPiper Sandler mantiene il rating Overweight su Crescent Biopharma, abbassa il prezzo obiettivo a 32 dollari. Piper Sandler mantiene il rating Overweight su Crescent Biopharma, abbassa il prezzo obiettivo a 32 dollari. Benzinga 2026.11.13 15:55 (GMT+0) Open on Benzinga Other news Citigroup Maintains Buy on Kodiak AI, Lowers Price Target to $7 Swoosh and a Miss: Nike Investor Day Leaves Wall Street Cold-Footed Wall Street Says the AI Trade Is Over — ETF Investors Aren’t Acting Like It Citigroup Maintains Neutral on Westlake, Lowers Price Target to $65 Citigroup Maintains Neutral on LyondellBasell Industries, Lowers Price Target to $66 Caterpillar's 'Best-In-Class' Construction Business Is Getting Overlooked, Analyst Says